FTC Sues Hims & Hers, Alleging Unlawful Sharing of Data, Deceptive Billing
By Kelly Cloonan
The Federal Trade Commission sued Hims & Hers Health, alleging the telehealth company shared users' information with third-party advertising platforms despite pledging to protect patient privacy.
The FTC, joined by Utah and California, also allege Hims & Hers deceived users about its billing and cancellation practices, charging patients before they met with providers and making it difficult to cancel subscriptions.
Hims & Hers disputed the lawsuit and said it would defend itself against the claims.
Shares of Hims & Hers declined 12%, to $25.75, on Wednesday. The stock is down 21% year to date.
According to the suit, Hims & Hers shared lists of certain customers, and the actions of visitors on its website, with advertisers such as Meta and Snap, even though it claimed its service maintains consumers' privacy.
Additionally, the FTC said Hims & Hers enrolls consumers in recurring subscription plans for treatments shortly after receiving their intake forms, despite claiming the users will be able to consult with medical providers to determine whether they need medication before getting charged.
The complaint also alleges that Hims & Hers makes it difficult to cancel subscriptions. The company fails to clearly inform users when their prescriptions will be refilled each month, making it tough to cancel before the next billing cycle, and hides an online cancellation button, according to the FTC.
The complaint alleges those practices violate both federal and state laws.
Hims & Hers said the suit disregards evidence it provided the FTC during the investigation and ignores industry standards in telehealth.
"This is not enforcement grounded in consumer protection; it is an effort to generate headlines at our expense," the company said in a statement.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
July 29, 2026 14:43 ET (18:43 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

The 10 Best Dividend Stocks

5 Stocks to Buy After Earnings

2 5-Star Stocks to Buy at Big Discounts

Tech Stocks Suffer Worst Week Since 2020 as Anthropic Faces Day Two Decline

